Quick Answer
Arcadia Biosciences, Inc. reported Stockholders Equity of $6.22 million for the year ending 2024.
- Arcadia Biosciences, Inc. showed a decrease of -51.5% in Stockholders Equity from 2023 to 2024.
- This data is from Arcadia Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$91.88 million | Q2 2015: $47.93 million | Q3 2015: $43.83 million | Q1 2016: $35.48 million | Q2 2016: $31.29 million | Q3 2016: $27.51 million | Q1 2017: $18.37 million | Q2 2017: $14.76 million | Q3 2017: $10.67 million | Q4 2017: $8.01 million | Q1 2018: $667.0 thousand | Q2 2018: $8.13 million | Q3 2018: $12.92 million | Q1 2019: $633.0 thousand | Q2 2019: $8.29 million | Q3 2019: $13.54 million | Q1 2020: $11.02 million | Q2 2020: $12.12 million | Q3 2020: $11.28 million | Q1 2021: $44.50 million | Q2 2021: $41.64 million | Q3 2021: $39.85 million | Q1 2022: $30.26 million | Q2 2022: $26.81 million | Q3 2022: $25.07 million | Q1 2023: $16.83 million | Q2 2023: $17.87 million | Q3 2023: $15.54 million | Q1 2024: $10.62 million | Q2 2024: $11.70 million | Q3 2024: $10.29 million.
- Over the full 12 years of available data (2013 to 2024), Arcadia Biosciences, Inc.'s Stockholders Equity has grown by 136.0%.
- Historical annual values: Fiscal year 2024: $6.22 million | Fiscal year 2023: $12.84 million | Fiscal year 2022: $21.03 million | Fiscal year 2021: $31.09 million | Fiscal year 2020: $27.73 million | Fiscal year 2019: $7.71 million | Fiscal year 2018: $12.82 million | Fiscal year 2017: $8.01 million | Fiscal year 2016: $22.20 million | Fiscal year 2015: $40.23 million | Fiscal year 2014: -$84.77 million | Fiscal year 2013: -$17.30 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: